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Background: Results from several cohort and case–control studies suggest a protective association between current alcohol
intake and risk of thyroid carcinoma, but the epidemiological evidence is not completely consistent and several questions remain
unanswered.
Methods: The association between alcohol consumption at recruitment and over the lifetime and risk of differentiated thyroid
carcinoma was examined in the European Prospective Investigation into Cancer and Nutrition. Among 477 263 eligible
participants (70% women), 556 (90% women) were diagnosed with differentiated thyroid carcinoma over a mean follow-up of 11
years. Hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated using multivariable Cox proportional hazards models.
Results: Compared with participants consuming 0.1–4.9 g of alcohol per day at recruitment, participants consuming 15 or more
grams (approximately 1–1.5 drinks) had a 23% lower risk of differentiated thyroid carcinoma (HR¼ 0.77; 95% CI¼ 0.60–0.98). These
findings did not differ greatly when analyses were conducted for lifetime alcohol consumption, although the risk estimates were
attenuated and not statistically significant anymore. Similar results were observed by type of alcoholic beverage, by differentiated
thyroid carcinoma histology or according to age, sex, smoking status, body mass index and diabetes.
Conclusions: Our study provides some support to the hypothesis that moderate alcohol consumption may be associated with a
lower risk of papillary and follicular thyroid carcinomas.
Thyroid carcinoma incidence rates have been rapidly increasing in
high-income countries, and the disease is more common among
women (Davies and Welch, 2006; Kilfoy et al, 2009). Differentiated
thyroid carcinoma, including papillary and follicular carcinoma,
represents 98% of thyroid cancer (Kilfoy et al, 2009; Dal Maso et al,
2011). The only well-defined risk factors for thyroid carcinoma are
exposure to ionizing radiation especially in childhood (Reynolds
et al, 2005), thyroid adenoma and history of goiter (Franceschi
et al, 1999; Balasubramaniam et al, 2012). Alcohol consumption is
an important correlate to other dietary and lifestyle factors, and
*Correspondence: Dr KK Tsilidis; E-mail: ktsilidi@cc.uoi.gr
Received 20 April 2015; revised 21 June 2015; accepted 2 July 2015; published online 27 August 2015
& 2015 Cancer Research UK. All rights reserved 0007 – 0920/15
FULL PAPER
Keywords: alcohol consumption; thyroid carcinoma; prospective study; lifetime exposure
British Journal of Cancer (2015) 113, 840–847 | doi: 10.1038/bjc.2015.280
840 www.bjcancer.com |DOI:10.1038/bjc.2015.280
results from several prospective (Galanti et al, 1997; Navarro
Silvera et al, 2005; Allen et al, 2009; Meinhold et al, 2009; Kabat
et al, 2012; Kitahara et al, 2012) and case–control studies (Rossing
et al, 2000; Mack et al, 2003) have suggested a protective
association between current moderate alcohol intake and thyroid
carcinoma risk. However, the extent of the lower risk has been
varying, and only two prospective studies of women from the
United Kingdom and the United States (Allen et al, 2009;
Meinhold et al, 2009) and a pooled-analysis of five prospective
studies on both sexes from the United States (Kitahara et al, 2012)
have shown statistically significant inverse associations. A few
smaller studies have observed null results (Iribarren et al, 2001;
Mack et al, 2002; Guignard et al, 2007). Data about alcohol intake
and thyroid carcinoma in men are limited, and no study has
previously reported on the association between lifetime alcohol
consumption and thyroid carcinoma risk. In the present large
study within the European Prospective Investigation into Cancer
and Nutrition (EPIC), we investigated the association between both
baseline and lifetime alcohol consumption with risk of differ-
entiated thyroid carcinoma, and also performed analyses by cancer
stage, type of alcoholic beverage and according to potential
modifying variables.
MATERIALS AND METHODS
Study design and recruitment. EPIC is a multicentre prospective
cohort study designed to investigate the relation between diet,
other lifestyle factors, environmental factors and cancer risk. The
cohort consists of approximately half a million participants, 70% of
which are women, mostly aged 35–70 years and recruited between
1992 and 2000 in 23 centres in 10 European countries, that is,
Denmark, France, Greece, Germany, Italy, the Netherlands,
Norway, Spain, Sweden and United Kingdom. The rationale,
design and data collection methods of EPIC have been previously
described in detail elsewhere (Riboli et al, 2002). This study was
approved by the Internal Review Boards of the International
Agency for Research on Cancer and of the participating centres.
Subjects were excluded if they had prevalent cancer (other than
non-melanoma skin cancer) at recruitment, if they were in the top
or bottom 1% of the distribution of the ratio of energy intake to
estimated energy requirement, and if they had missing information
on baseline alcohol consumption. Therefore, this study used data
from 477 263 participants, 335 020 (70%) of whom were women.
Assessment of thyroid carcinoma. Data on incident cases of
thyroid carcinoma were collected by linkage to regional or national
cancer registries from all EPIC centres except those from Greece,
France and Germany. Outcome follow-up data from these
countries were based on a combination of methods, including
the use of health insurance records, contact with cancer and
pathology registries, and active follow-up. Closure dates for the
present study were defined as the latest update for both cancer
incidence and vital status, that is, between 11 December 2006 and
14 June 2010 according to EPIC centre. A total of 556 incident
differentiated thyroid carcinoma cases (defined according to the
International Classification of Diseases, ICD-10 code C73) were
identified after an average follow-up of 11 years, 435 of which had
papillary, 76 had follicular and another 45 had unknown or other
carcinoma morphology. Thyroid cancer cases with anaplastic
(n¼ 6), medullary (n¼ 28), lymphoma (n¼ 1) and other rare
morphologies (n¼ 3), which are usually considered poorly
differentiated tumours with lower cure rates, were excluded. Data
on the stage of differentiated thyroid carcinomas at diagnosis were
collected from each centre, where possible. A total of 372 cases
(67%) had stage information, of which 266 were classified
as localised (tumour-node-metastasis staging score of T0–T2 and
N0/Nx and M0, or stage coded in the recruitment centre as
localised) and 106 were classified as advanced thyroid carcinoma
(T3–T4 and/or N1–N3 and/or M1, or stage coded in the recruitment
centre as metastatic).
Assessment of alcohol intake and other variables. Dietary
assessment was performed by self-administrated country- or
centre-specific dietary questionnaires or food records (Riboli
et al, 2002). The intake of alcoholic beverages at baseline was
calculated from these questionnaires that have been previously
validated for alcohol consumption (Kaaks et al, 1997; Riboli et al,
2002; Hjartaker et al, 2007). Participants reported the number of
standard glasses of beer, wine and distilled spirits consumed per
day or week during the 12 months before recruitment. Alcohol
intake was calculated by multiplying the mean glass volume with
the alcohol content for each type of alcoholic beverage (Slimani
et al, 2007), using information collected in standardised 24-h
dietary recalls from a subset of the cohort (Slimani et al, 2000).
Information of past alcohol consumption was assessed as glasses of
different beverages consumed per week at 20, 30, 40 and 50 years
of age in all EPIC centres except for Naples, Bilthoven, Umea,
Malmo and Norway (Klipstein-Grobusch et al, 2007). Average
lifetime alcohol intake was determined as a weighted average of
intake at different ages with weights equal to the time of individual
exposure to alcohol at different ages.
Information on physical activity, smoking status, level of
education, diagnosis of diabetes mellitus, and in women only,
age at menarche and menopause, use of oral contraceptives and
hormone replacement therapy and number of full-term pregnan-
cies (defined as the sum of live and still births) was self-reported at
the baseline questionnaire (Tsilidis et al, 2011a, b). Weight and
height were measured at recruitment, except for most of
the Oxford cohort, the Norwegian cohort, and approximately
two-thirds of the French cohort, among whom weight and height
were self-reported. Body mass index (BMI) was calculated as
weight in kilograms divided by height in metres squared.
Menopausal status was defined according to information
on menstruation status, hysterectomy, ovariectomy, use of
exogenous hormone and age, details of which are provided
elsewhere (Tsilidis et al, 2011b).
Statistical analysis. Cox proportional hazard models were used to
study the association between alcohol intake and differentiated
thyroid carcinoma incidence using age as the underlying time scale.
Age at entry was defined as the participants’ age at recruitment,
and exit time was age at diagnosis of thyroid cancer, death, loss to
follow-up or censoring at the end of the follow-up period,
whichever came first. The proportionality of hazards was verified
based on the slope of the Schoenfeld residuals over time, and no
evidence of violation was detected. The models were stratified by
study centre to control for differences in questionnaires and
follow-up procedures, and for sex and age at recruitment in 5-year
categories. All multivariate models were adjusted for known or
suspected risk factors of thyroid carcinoma, such as smoking status
(never, former quitted p10 years ago, former quitted 11–20 years
ago, former quitted 420 years ago, current with 1–15 cigarettes
per day, current with 16–25 cigarettes per day, current with 425
cigarettes per day, current with pipe/cigar or occasional cigarette
use, missing), education (up to high school, university graduate,
missing), BMI (in quintiles, missing), physical activity (inactive,
moderate inactive, moderate active, active, missing), diabetes status
(no, yes, missing), energy from non-alcohol sources (continuously
in kcals) and hormone replacement therapy (never, former,
current, missing), use of oral contraceptives (never, former,
current, missing), age at menarche (o12, 12, 13, 14, X15,
missing), number of full-term pregnancies (0, 1, 2, 3,X4, missing)
and menopausal status in women (premenopausal, perimenopau-
sal, postmenopausal). Missing values were assigned to separate
Alcohol consumption and differentiated thyroid carcinoma BRITISH JOURNAL OF CANCER
www.bjcancer.com |DOI:10.1038/bjc.2015.280 841
categories for smoking status (4%), education (3.6%), BMI (0.8%),
physical activity (8.8%), diabetes (3.5%), hormone replacement
therapy (10.8%), oral contraceptives (3.2%), age at menarche
(2.3%) and full-term pregnancies (5.8%) – and missing indicators
were used in the statistical models. Analyses that excluded
participants with missing values for any of these covariates, and
analyses that included further adjustments for currently having a
paid employment, waist circumference, hip circumference, waist to
hip ratio, self-reported personal history of thyroid diseases and
infertility problems gave very similar results and are not presented
here. When we further adjusted the lifetime alcohol consumption
models for an indicator variable for participants who quitted
alcohol drinking and for time since alcohol quitting to deal with
the potential existence of former drinkers who quitted drinking
because of an illness (Shaper et al, 1988), the results remained very
similar and are not presented.
Baseline and average lifetime consumption of total alcohol were
modelled primarily as categorical variables based on the distribu-
tion of intake in EPIC (0, 0.1–4.9, 5–14.9, X15 g per day) after
evaluating non-parametric lowess plots of alcohol on thyroid
cancer risk for non-linearity. Alcohol consumption of 0.1–4.9 g per
day was used as the reference category in all statistical models to
allow for comparisons with the non-consumer category. In
addition, non-consumers might be a biased group as some
participants may have stopped drinking due to ill health. However,
when different cutpoints of alcohol consumption were used (0,
0.1–4.9, 5–14.9, 15–29.9,X30 or 0, 0.1–2.9, 3–9.9, 10–19.9,X20 g
per day or quartiles based on the distribution in the whole cohort
or in each EPIC centre) or when the non-consumers were the
reference category, the results were very similar and are not
presented. Alcohol consumption was also evaluated using a
continuous variable per 10 g per day or 3 g per day, depending
upon the range of intake of each alcoholic beverage, after adjusting
for consumer vs non-consumer status using an indicator variable
or after performing analyses only among consumers. Alcohol
consumption of 10 g per day equals approximately to a small glass
of wine (100ml), a can of beer (330ml) or a shot of spirit (30ml).
Separate analyses were performed by type of alcohol consumption
(beer, wine, spirits) after mutually adjusting each time for energy
obtained from the other two types of beverages. Non-consumers
were defined here as participants who did not consume the
alcoholic beverage under evaluation, but could consume other
alcoholic beverages.
To evaluate whether the association of alcohol intake with
thyroid cancer risk differed by age at recruitment (o50 vs X50
years), sex, smoking status (never, former, current smokers), BMI
(o25 vs X25 kgm 2) and diabetes (no vs yes), interaction terms
were incorporated in the multivariable models and its significance
assessed with Wald tests. Country-specific analyses were also
performed, and heterogeneity of associations across countries (and
by type of alcoholic beverage) were assessed using Cochran’s
Q-test and the I2 metric of inconsistency (Higgins et al, 2003).
A sensitivity analysis was conducted excluding the first two years of
follow-up to limit the likelihood that the observed associations
were due to change of alcohol consumption produced by extant
cancers, but the results were very similar to the main analysis and
are not shown. All P-values (P) were two-sided and all analyses were
performed using STATA version 12 (College Station, TX, USA).
RESULTS
Table 1 describes the distribution of participant characteristics at
recruitment by country in the EPIC study. The mean age at
enrolment in the cohort was 51 years and 70% of the participants
were women. The majority of the 556 differentiated thyroid
carcinoma cases, 90% (n¼ 499) of which occurred in women, were
identified in France (n¼ 202) followed by Italy (n¼ 82) and
Germany (n¼ 79). Of the 477 263 total participants, 14% were
non-consumers of alcohol at baseline (17% in women and 7% in
men), and 25% consumed 15 or more grams of alcohol per day
(16% in women and 45% in men), a percentage that ranged from
1% in Norway (100% of Norwegian participants were women) to
46% in Denmark (52% of Danish participants were women). The
mean baseline alcohol consumption among consumers was 13.5 g
per day (9.5 g per day in women and 21.8 g per day in men),
whereas it was almost 14 g per day when alcohol consumption
during lifetime was considered. Overall, the female participants in
EPIC had a low-to-moderate alcohol consumption with very few
heavy drinkers in the data set (only 5% of the female population
had alcohol intake of 433.5 g per day and 1% of the population
had intake of 456.9 g per day at recruitment). Men consumed on
average more alcohol than women with B25% consuming more
than 31 g per day at recruitment.
Table 2 presents sex-specific frequencies of selected baseline
characteristics by categories of baseline alcohol intake adjusted for
country and age at recruitment. Compared with women consum-
ing no alcohol, alcohol consumers had on average a higher level of
education, were more likely to be current or ever smokers, were
more physically active, were more likely to be ever users of
hormone replacement therapy and oral contraceptives, were less
likely to be postmenopausal and have diabetes and were on average
leaner. These associations generally increased linearly with
increasing alcohol consumption. Similar but smaller in magnitude
differences were observed among men with the exception of mean
BMI, which was similar across alcohol consumption categories.
Table 3 reports hazard ratios (HRs) and 95% confidence
intervals (CIs) for the associations of baseline and lifetime alcohol
intake with differentiated thyroid carcinoma risk. Compared with
men and women consuming 0.1–4.9 g of alcohol per day at
recruitment, individuals consuming 15 or more grams per day had
a 24% lower risk of differentiated thyroid carcinoma (HR¼ 0.76;
95% CI¼ 0.60–0.97) in age, sex and centre stratified models.
Further adjustment for smoking, education, BMI, physical activity,
diabetes, energy from non-alcohol sources, hormone replacement
therapy, oral contraceptives, age at menarche, number of full-term
pregnancies and menopausal status yielded an identical association
(HR¼ 0.77; 95% CI¼ 0.60–0.98). Non-consumers of alcohol at
recruitment were at a similar risk for thyroid carcinoma
(HR¼ 0.97; 95% CI¼ 0.76–1.25) compared with consumers of
0.1–4.9 g per day. For every 10 g of alcohol consumed per day
among consumers, the risk of thyroid carcinoma was lowered by
9% (HR¼ 0.91; 95% CI¼ 0.84–0.98). Very similar and statistically
significant associations were observed for intake of alcohol from
wine (HR per 10 g per day among consumers¼ 0.91 (0.82–0.99)).
The risk estimates were smaller and not statistically significant for
beer (HR per 3 g per day among consumers¼ 0.96; 95% CI¼ 0.90–
1.03) and spirits intake (HR per 3 g per day among
consumers¼ 0.99; 95% CI¼ 0.89–1.10), but overall the associa-
tions by type of alcoholic beverage did not differ from each other
(P-heterogeneity¼ 0.38; I2¼ 0%).
When analyses were performed for lifetime alcohol intake,
similar associations with the alcohol at baseline analyses were
observed, but the risk estimates for total alcohol and alcohol from
wine intake and thyroid carcinoma risk were attenuated and were
not statistically significant anymore (Table 3). The HR per 10 g per
day of total lifetime alcohol intake among consumers was 0.93
(95% CI¼ 0.84–1.02). Moreover, similar results were observed for
baseline and lifetime alcohol intake and risk of papillary thyroid
carcinoma (Supplementary Table 1) as well as by thyroid
carcinoma stage (Supplementary Tables 2 and 3).
No statistically significant interactions were observed for
total baseline or lifetime alcohol consumption and thyroid
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carcinoma risk according to age at recruitment, sex, BMI, smoking
status or diabetes (Table 4). When analysis was performed by
EPIC-participating country, the risk estimates were relatively
homogeneous (alcohol intake at baseline: P-heterogeneity¼ 0.35;
I2¼ 10%; average lifetime alcohol intake: P-heterogeneity¼ 0.63;
I2¼ 0%).
DISCUSSION
In this large prospective study involving 477 263 participants and
556 incident differentiated thyroid carcinoma cases, we observed
that moderate alcohol intake at recruitment was associated with a
statistically significant lower risk of thyroid carcinoma. These
findings did not materially differ by whether baseline or lifetime
alcohol consumption was considered, although the risk estimates
for lifetime alcohol and thyroid carcinoma were not nominally
statistically significant, by type of alcoholic beverage, by thyroid
carcinoma histology and stage, or according to age, sex, BMI,
smoking status and diabetes.
In parallel to our findings, several large cohort (Galanti et al,
1997; Navarro Silvera et al, 2005; Allen et al, 2009; Meinhold et al,
2009; Kabat et al, 2012; Kitahara et al, 2012) and case–control
(Rossing et al, 2000; Mack et al, 2003) studies have also reported
suggestive inverse associations for moderate alcohol intake at
recruitment and risk of thyroid carcinoma. The Million Women
Study enrolled 1 280 296 women in the United Kingdom, 491 of
which developed incident thyroid cancer during an average of 7.2
years of follow-up. Compared with women consuming less than
two drinks per week, those consuming more than 15 drinks per
week had a statistically significant 46% lower risk (HR¼ 0.54; 95%
CI¼ 0.31–0.92; Allen et al, 2009). The Women’s Health Initiative
cohort study, which included 159 340 post-menopausal women
with 331 incident thyroid cancer cases, reported a borderline
significant inverse association comparing women consuming at
least seven drinks per week vs none (HR¼ 0.66; 95% CI¼ 0.44–
1.01; Kabat et al, 2012). A pooled analysis of five prospective
studies from the United States (Kitahara et al, 2012) that included
384 443 men, 361 664 women and 1003 incident thyroid cancers
showed a HR of 0.72 (95% CI¼ 0.58–0.90) for an alcohol intake of
X7 drinks per week vs zero, that is, an inverse association of
similar magnitude to the one we observed in EPIC.
The evidence for an association between alcohol consumption
and risk of differentiated thyroid carcinoma in men is sparse,
because this disease is much more common among women. In
EPIC, we observed that moderate alcohol consumption at baseline
or during the lifetime was associated with a lower but not
statistically significant risk of differentiated thyroid carcinoma in
men. Studies that have reported results in men and women have
generally not observed significantly different findings by sex
(Galanti et al, 1997; Guignard et al, 2007; Meinhold et al, 2009;
Kitahara et al, 2012), in agreement with our findings. Moreover,
other studies have also not observed great differences in the
associations of alcohol and thyroid carcinoma by type of alcoholic
beverage, by thyroid carcinoma histology, by age, BMI or smoking
status at recruitment (Galanti et al, 1997; Allen et al, 2009;
Meinhold et al, 2009; Kabat et al, 2012; Kitahara et al, 2012), in
agreement with findings in EPIC.
The mechanisms explaining the potential link between alcohol
consumption and differentiated thyroid carcinoma risk are not well
known and are potentially complex. Some studies have described
thyroid dysfunction in alcoholic individuals, and have suggested
either a direct toxic effect of alcohol on the thyroid or a disturbance
on the hypothalamus–pituitary–thyroid axis (Hegedus et al, 1988;
Zoeller et al, 1996). However, the potential effects of low-to-
moderate alcohol consumption on the thyroid are much less
studied and should be considered speculative. Alcohol metabolism
results in generation of free radicals, which has been hypothesised
to induce oxidative stress in tissues poorly metabolising alcohol,
such as the thyroid, and subsequently lead to hypothalamus–
pituitary–thyroid axis dysfunction and reduction of peripheral
thyroid hormone concentrations (Valeix et al, 2008). However, a
recent nested case–control study in EPIC did not find an
association between pre-diagnostic concentrations of total or free
T3 and T4 with differentiated thyroid carcinoma risk, although
Tg and TSH concentrations were significantly associated with
the disease in a positive and negative manner, respectively (Rinaldi
et al, 2014).
The present study has a number of strengths, including its
prospective nature that precludes reverse causation to a large
extent, and the large size of the EPIC cohort that gave rise to the
largest number of differentiated thyroid carcinoma cases to date by
any single cohort study. In addition, information on the
histological subtype and stage of thyroid cancer and on drinking
habits at recruitment and over lifetime as well as data on a wide
Table 1. Distribution of participant characteristics at recruitment in the EPIC cohort by country
All Denmark France Germany Greece Italy Netherlands Norway Spain Sweden UK
(n¼477263) (n¼55006) (n¼67375) (n¼48576) (n¼26028) (n¼44533) (n¼36502) (n¼35167) (n¼39997) (n¼48682) (n¼75397)
Mean age, years 50.7 56.2 52.2 50.1 52.6 50 48.5 47.6 48.7 51.5 48.8
Female, n (%) 335 018 (70.2) 28 715 (52.2) 67375 (100) 27 405 (56.4) 15 223 (58.5) 30 506 (68.5) 26 864 (73.6) 35 167 (100) 24 852 (62.1) 26370 (54.2) 52 543 (69.7)
Person years 5 414700 625248 704066 495537 251145 515726 443810 351003 493373 669902 864889
No. of cases, n 556 23 202 79 24 82 12 30 51 24 29
Baseline alcohol intake, n (%)
Non-consumer 66664 (14.0) 1235 (2.2) 9484 (14.0) 2217 (4.6) 6485 (24.9) 7435 (16.7) 5763 (15.8) 7254 (20.6) 15 346 (38.4) 6814 (14.0) 4631 (6.1)
0.1–4.9 164 560 (34.5) 10 654 (19.4) 21683 (32.2) 15 375 (31.7) 9249 (35.5) 13 658 (30.6) 12 526 (34.3) 20 778 (59.1) 7587 (18.9) 22206 (45.6) 30 844 (41.0)
5.0–14.9 127 520 (26.7) 18 041 (32.8) 18980 (28.2) 13 482 (27.7) 5304 (20.4) 9828 (22.1) 8734 (23.9) 6768 (19.2) 5993 (15.0) 13222 (27.2) 27 168 (36.0)
X15 118519 (24.8) 25 076 (45.6) 17228 (25.6) 17 502 (36.0) 4990 (19.2) 13 612 (30.6) 9479 (26.0) 367 (1.1) 11 071 (27.7) 6440 (13.2) 12 754 (16.9)
Mean, g per da 13.5 21.1 12.7 16.6 12.6 16.3 13.1 3.5 21.5 7.9 9.6
Lifetime alcohol intake, n (%)
Non-consumer 37949 (8.0) 1750 (3.2) 9924 (14.8) 722 (1.5) 5680 (21.8) 4934 (11.1) 1835 (5.0) NA 10389 (26.0) NA 2715 (3.6)
0.1–4.9 120 726 (25.3) 11 712 (21.3) 28409 (42.2) 16 561 (34.1) 8396 (32.3) 12 756 (28.6) 6318 (17.3) NA 9042 (22.6) NA 27532 (36.5)
5.0–14.9 109 502 (22.9) 22 081 (40.1) 19639 (29.1) 15 297 (31.5) 5096 (19.6) 10 140 (22.8) 5101 (14.0) NA 6911 (17.3) NA 25237 (33.5)
X15 95022 (19.9) 19 217 (40.0) 8445 (12.5) 15 995 (32.9) 6856 (26.3) 11 566 (26.0) 2158 (5.9) NA 13407 (33.5) NA 17378 (23)
Unknown 11406 (23.9) 246 (0.4) 958 (1.4) 1 (0) NA 5137 (11.5) 21 090 (57.8) 35 167 (100) 248 (0.6) 48682 (100) 2535 (3.4)
Mean, g per da 13.9 15.1 7.9 16.3 18.9 14.3 8.2 NA 25.4 NA 11.0
Abbreviations: EPIC¼European Prospective Investigation into Cancer and Nutrition; UK¼United Kingdom; NA¼ not available.
aMean values of alcohol consumption only among alcohol consumers.
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Table 2. Country and age-adjusted participant characteristics by categories of baseline alcohol intake and sex in the EPIC cohorta
Baseline alcohol intake (g per day)
Characteristics Non-consumers 0.1–4.9 5.0–14.9 X15
Women (n¼335018)
Mean age (s.d.), years 51.8 (9.9) 49.6 (9.9) 50.1 (9.9) 51.2 (9.9)
University graduate, % 12.1 19.0 26.0 29.4
Current smoker, % 18.8 17.5 18.3 27.6
Ever smoker, % 34.2 40.6 45.8 56.8
Physically active, % 23.5 32.9 39.7 43.0
Ever hormone replacement therapy users,% 17.4 23.2 25.5 27.6
Ever oral contraceptive users, % 42.0 57.6 65.9 69.2
Parous, % 90.3 87.9 85.4 84.1
Postmenopausal (naturally or surgically), % 45.4 42.3 39.3 38.1
Diabetes, % 3.6 2.0 1.3 1.3
Mean body mass index (s.d.), kgm2 26.6 (4.14) 25.2 (4.13) 24.6 (4.12) 24.4 (4.15)
Mean energy from non-alcohol (s.d.), kcal per day 1811 (554) 1847 (553) 1895 (552) 1913 (555)
Men (n¼142245)
Mean age (s.d.), years 53.5 (9.9) 50.7 (9.9) 51.3 (9.9) 51.9 (9.9)
University graduate, % 15.3 22.4 29.7 29.9
Current smoker, % 30.2 22.0 23.4 33.8
Ever smoker, % 63.7 55.2 60.3 73.4
Physically active, % 41.7 46.0 48.9 52.2
Diabetes, % 4.9 3.4 2.5 2.6
Mean body mass index (s.d.), kgm2 26.8 (4.12) 26.3 (4.12) 26.3 (4.12) 26.7 (4.14)
Mean energy from non-alcohol (s.d.), kcal per day 2297 (552) 2243 (552) 2293 (554) 2322 (554)
Abbreviations: EPIC¼European Prospective Investigation into Cancer and Nutrition; s.d.¼ standard deviation.
aCountry and age at recruitment-adjusted means with standard deviations are presented for continuous variables and percentage for categorical variables using linear and logistic regression
models, respectively.
Table 3. Association of alcohol intake and differentiated thyroid carcinoma in the EPIC cohort
Intake at baseline Average lifetime intakea
Cases/cohort HRb (95% CI) HRc (95% CI) Cases/cohort HRb (95% CI) HRc (95% CI)
Total alcohol (g per day)
0 98/66 566 0.98 (0.76–1.26) 0.97 (0.76–1.25) 81/37 868 1.16 (0.89–1.52) 1.16 (0.89–1.52)
0.1–4.9 224/164 336 1.00 (reference) 1.00 (reference) 201/120 525 1.00 (reference) 1.00 (reference)
5–14.9 127/127 393 0.76 (0.61–0.94) 0.76 (0.61–0.95) 125/109 377 0.86 (0.68–1.08) 0.86 (0.69–1.08)
X15 107/118 412 0.76 (0.60–0.97) 0.77 (0.60–0.98) 76/94 946 0.90 (0.68–1.21) 0.90 (0.67–1.21)
Per 10 g per dayd 458/410 141 0.91 (0.84–0.98) 0.91 (0.84–0.98) 402/324 848 0.93 (0.84–1.02) 0.93 (0.84–1.02)
Alcohol from wine (g per day)
0e 124/98 185 0.95 (0.75–1.21) 0.94 (0.75–1.19) 102/63 771 1.07 (0.83–1.38) 1.07 (0.83–1.37)
0.1–4.9 244/194 805 1.00 (reference) 1.00 (reference) 232/161 738 1.00 (reference) 1.00 (reference)
5–14.9 116/116 785 0.80 (0.63–0.99) 0.81 (0.64–1.01) 110/91 736 0.94 (0.74–1.19) 0.94 (0.75–1.19)
X15 72/66 932 0.74 (0.56–0.97) 0.75 (0.57–0.99) 112/159 462 0.81 (0.56–1.17) 0.81 (0.56–1.17)
Per 10 g per dayd 458/410 141 0.90 (0.82–0.99) 0.91 (0.82–0.99) 402/324 848 0.96 (0.84–1.09) 0.96 (0.84–1.09)
Alcohol from beer (g per day)
0f 321/213 960 1.10 (0.88–1.38) 1.09 (0.87–1.37) 255/150 311 1.01 (0.79–1.28) 1.00 (0.79–1.28)
0.1–0.9 118/89 139 1.00 (Reference) 1.00 (Reference) 109/70 825 1.00 (Reference) 1.00 (Reference)
1.0–2.9 54/71 768 0.77 (0.55–1.07) 0.77 (0.55–1.07) 60/55 400 0.97 (0.70–1.34) 0.98 (0.71–1.35)
X3 63/101 840 0.90 (0.65–1.26) 0.90 (0.64–1.25) 59/86 180 1.06 (0.74–1.53) 1.07 (0.74–1.54)
Per 3 g per dd 458/410 141 0.96 (0.90–1.03) 0.96 (0.90–1.03) 402/324 848 0.99 (0.92–1.07) 0.99 (0.92–1.07)
Alcohol from spirits (g per day)
0g 384/273 418 1.10 (0.86–1.41) 1.10 (0.86–1.41) 312/179 769 1.27 (0.97–1.66) 1.28 (0.98–1.68)
0.1–0.9 106/102 921 1.00 (Reference) 1.00 (Reference) 79/63 692 1.00 (Reference) 1.00 (Reference)
1.0–2.9 38/44 975 0.89 (0.61–1.29) 0.88 (0.60–1.29) 52/55 831 1.17 /0.82–1.68) 1.16 (0.81–1.66)
X3 28/55 393 0.82 (0.53–1.27) 0.81 (0.52–1.25) 40/63 424 1.25 (0.82–1.91) 1.21 (0.79–1.84)
Per 3 g per dd 458/410 141 1.00 (0.90–1.10) 0.99 (0.89–1.10) 402/324 848 0.92 (0.81–1.03) 0.91 (0.80–1.03)
P-heterogeneity by type of beveraged; I2 0.38; 0% 0.42; 0%
Abbreviations: EPIC¼European Prospective Investigation into Cancer and Nutrition; HR¼hazard ratio; CI¼ confidence interval.
aThis information was missing for participants from the EPIC centres of Naples, Bilthoven, Umea, Malmo and Norway.
bFrom Cox proportional hazard models stratified by centre and age at recruitment; alcohol intake of one alcoholic beverage is mutually adjusted for the intake of the other two beverages.
cFrom Cox proportional hazard models stratified by centre and age at recruitment and adjusted for cigarette smoking intensity, education, body mass index, physical activity, diabetes, energy
from non-alcohol sources, hormone replacement therapy, oral contraceptives, age at menarche, number of full-term pregnancies and menopausal status; alcohol intake of one alcoholic
beverage is mutually adjusted for the intake of the other two beverages.
dAmong consumers of alcoholic beverages only. When we performed analyses including both consumers and non-consumers of alcoholic beverages but after adjusting for being a consumer
or not, the results were identical.
eThis group includes participants who did not consume wine, but consumed other alcoholic beverages.
fThis group includes participants who did not consume beer, but consumed other alcoholic beverages.
gThis group includes participants who did not consume spirits, but consumed other alcoholic beverages.
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range of potential confounders is important and unique aspects of
this study.
However, the study also has limitations. First, most women in
the EPIC cohort, and in most other published epidemiological
studies, were consuming low to moderate amounts of alcohol at
enrolment or over their lifetimes, which did not allow investigating
the association of heavy sustained drinking on subsequent risk of
thyroid carcinoma. Second, information on alcohol consumption
at baseline and over the lifetime was self-reported, but due to the
prospective nature of the study this is likely to lead to non-
differential misclassification (by thyroid carcinoma cases and non-
cases) and bias, if any, our results towards the null. However, the
information on alcohol consumption at recruitment in EPIC has
been shown to be adequately reliable and valid compared with
repeat food frequency questionnaires and multiple 24-h diet recalls
(Kaaks et al, 1997). Third, data on ionizing radiation exposure and
medical history of benign thyroid diseases, the most well-
established risk factors for thyroid cancer were not available in
EPIC and confounding due to these variables could not be assessed.
However, adjustment for radiation and benign thyroid conditions
in a prior publication had little influence on the associations
(Kitahara et al, 2012). In addition, all of our risk estimates were
adjusted for several confounding factors with relatively small
difference to the risk estimates compared with unadjusted models.
Besides that we cannot rule out the possibility of residual
confounding by other unmeasured factors. Finally, individuals
with a healthy lifestyle who may consume little or no alcohol might
be prone to have their thyroids examined or removed surgically,
and thus maybe have an incidental finding of a small localised
thyroid cancer without clinical relevance, which could explain the
weak inverse association observed in this study. However, this
potential detection bias is unlikely to have driven our findings,
because risk estimates did not differ between analyses for localised
and advanced thyroid carcinomas.
In conclusion, our prospective study provides some support to
the hypothesis that moderate alcohol consumption may be
associated with a lower risk of differentiated thyroid carcinoma.
However, more studies are needed to fully characterise the nature
and mechanisms underlying this association. Given that many
studies have reported an increased risk of various forms of cancer
with alcohol intake, the findings of this study do not change the
current public health recommendation that if alcoholic beverages
are consumed, consumption should be limited to no more than
two drinks a day for men and one drink a day for women
(World Cancer Research Fund/American Institute for Cancer
Research, 2007).
Table 4. Association of alcohol intake (per 10g per day among consumers) and differentiated thyroid carcinoma by subgroups in
the EPIC cohort
Intake at baseline Average lifetime intakea
Subgroups Cases/cohort HRb (95% CI) Cases/cohort HRb (95% CI)
Country
Denmark 22/53 749 1.02 (0.81–1.27) 22/52 988 0.97 (0.66–1.43)
France 174/57 717 0.91 (0.81–1.03) 166/56 327 0.92 (0.77–1.10)
Germany 76/46 283 0.79 (0.62–0.99) 79/47 774 0.84 (0.65–1.09)
Greece 17/19 526 1.04 (0.76–1.41) 17/20 331 0.71 (0.41–1.22)
Italy 63/37 035 0.96 (0.81–1.13) 57/34 405 0.99 (0.81–1.22)
Norway 27/27 886 0.54 (0.15–1.99) NA NA
Spain 23/24 628 1.06 (0.75–1.50) 28/29 332 1.08 (0.92–1.27)
Sweden 18/41 850 0.77 (0.35–1.67) NA NA
The Netherland 11/30 728 0.11 (0.02–0.81) 7/13 570 0.96 (0.35–2.64)
United Kingdom 27/70 739 0.84 (0.54–1.29) 26/70 121 0.79 (0.50–1.25)
P-heterogeneity; I2 0.35; 10% 0.63; 0%
Age at recruitment (years)
o50 222/175 102 0.90 (0.80–1.02) 191/125 040 0.86 (0.73–1.00)
X50 236/235 039 0.91 (0.82–1.01) 211/191 352 0.97 (0.87–1.09)
P-interaction 0.94 0.24
Sex
Male 52/132 480 0.94 (0.82–1.09) 46/102 326 0.94 (0.82–1.07)
Female 406/277 661 0.89 (0.81–0.98) 356/214 066 0.91 (0.80–1.04)
P-interaction 0.80 0.86
Body mass index
o25 kgm 2 259/210 776 0.88 (0.79–0.99) 223/160 200 0.88 (0.75–1.03)
X25 kgm 2 199/199 365 0.93 (0.84–1.04) 179/156 192 0.96 (0.85–1.08)
P-interaction 0.43 0.26
Smoking status
Never smoker 244/192 158 0.83 (0.72–0.95) 223/155 952 0.80 (0.66–0.98)
Former smoker 118/115 574 0.90 (0.77–1.03) 104/88 406 0.99 (0.87–1.14)
Current smoker 84/94 199 0.99 (0.87–1.12) 66/67 058 0.92 (0.77–1.10)
P-interaction 0.11 0.60
Diabetes
No 440/386 254 0.90 (0.83–0.98) 392/301 062 0.93 (0.84–1.02)
Yes 8/9353 1.17 (0.82–1.66) 8/8026 0.97 (0.64–1.46)
P-interaction 0.78 0.41
Abbreviations: EPIC¼European Prospective Investigation into Cancer and Nutrition; HR¼hazard ratio; CI¼ confidence interval; NA¼not applicable.
aThis information was missing for participants from the EPIC centres of Naples, Bilthoven, Umea, Malmo, and Norway.
bFrom Cox proportional hazard models stratified by centre and age at recruitment and adjusted for cigarette smoking intensity, education, body mass index, physical activity, diabetes, energy
from non-alcohol sources, hormone replacement therapy, oral contraceptives, age at menarche, number of full-term pregnancies and menopausal status.
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